Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Genetics, Mosaicism, and Precision Medicine in Vascular Anomalies
Description
The speaker discussed how genetics is transforming diagnosis and treatment of vascular anomalies, emphasizing that most are not inherited genomic disorders but post-zygotic somatic mosaic conditions. Because the mutation may be present only in affected tissue, blood testing often misses the diagnosis, so high-depth sequencing of biopsied lesion tissue is crucial. The talk organized vascular anomalies into major molecular pathways—especially PIK3CA, GNAQ/GNA11, and RAS/MAPK-related genes—and showed how the same clinical appearance can reflect very different mutations, while the same mutation can produce different phenotypes depending on when and where it occurs in embryogenesis. Through many case examples, the speaker illustrated how genotype and lesion distribution guide screening for complications such as glaucoma, leptomeningeal disease, macrocephaly, seizures, and internal AVMs, and how bedside clues like flow, reticulation, and segmental versus multifocal distribution help narrow the diagnosis. The speaker also highlighted germline conditions like RASA1 and EPHB4, the importance of full physical examination and imaging tailored to molecular findings, and the concept of a molecular taxonomy rather than purely descriptive classification. Finally, the talk stressed that these discoveries are enabling precision medicine, including targeted therapies such as PI3K and MEK pathway inhibitors for selected patients.
View moreConclusions
- Most vascular anomalies are driven by postzygotic somatic mosaic mutations, so the affected tissue—not blood alone—must be tested to find the causal variant.
- Vascular anomalies can be better understood and classified by molecular pathway than by appearance alone, with major groups including GNAQ/GNA11, PIK3CA/PI3K, and RAS/MAPK-related lesions.
- The same outward skin phenotype can arise from different genes, and the same gene can produce very different disease severity depending on the specific mutation and its embryologic timing and location.
- Clinical pattern, lesion distribution, flow characteristics, and associated findings such as glaucoma, brain involvement, or overgrowth remain essential for directing diagnosis and screening.
- Mutational load and anatomic distribution strongly influence morbidity, explaining why localized mosaicism may be mild while early or widespread mosaicism can cause severe multisystem disease.
- Precise genotype-phenotype matching can prevent unnecessary screening in some patients while prompting appropriate brain, spine, or ocular evaluation in others.
- Different vascular lesions that look similar at bedside can behave differently biologically and therapeutically, so treatment should be guided by molecular diagnosis rather than appearance alone.
- Targeted therapy, including PI3K inhibition and MEK-pathway targeting in selected cases, can produce meaningful clinical improvement in appropriately genotyped patients.
- Overall, integrating careful physical examination, imaging, and high-depth molecular testing enables more accurate diagnosis, surveillance, and precision treatment for patients with vascular anomalies.
- Moving towards a molecular taxonomy of autoimmune rheumatic diseases.#10.1038/nrrheum.2017.220